Home Cart Sign in  
Chemical Structure| 2680-81-1 Chemical Structure| 2680-81-1

Structure of Dehydrodiisoeugenol
CAS No.: 2680-81-1

Chemical Structure| 2680-81-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Dehydrodiisoeugenol, a natural product isolated and purified from the seeds of Myristica fragrans Houtt.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Dehydrodiisoeugenol

CAS No. :2680-81-1
Formula : C20H22O4
M.W : 326.39
SMILES Code : OC1=CC=C(C2OC3=C(OC)C=C(/C=C/C)C=C3C2C)C=C1OC
MDL No. :N/A
InChI Key :ITDOFWOJEDZPCF-AATRIKPKSA-N
Pubchem ID :5379033

Safety of Dehydrodiisoeugenol

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Dehydrodiisoeugenol

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MCF-10A 56.80 μM (IC50) 48 h No killing effect on normal breast epithelial cells Front Pharmacol. 2025 Feb 28;16:1545498
MCF-7 15.96 μM (IC50) 48 h Inhibited breast cancer cell proliferation by blocking the G0/G1 phase of the cell cycle Front Pharmacol. 2025 Feb 28;16:1545498
MDA-MB-231 14.98 μM (IC50) 48 h Inhibited breast cancer cell proliferation by blocking the G0/G1 phase of the cell cycle Front Pharmacol. 2025 Feb 28;16:1545498
NCM460 cells 0.001-1000 μM 48 h The IC50 of DEH on NCM460 cells was significantly higher than that on HCT 116 and SW620 cells, indicating lower toxicity to normal cells. J Exp Clin Cancer Res. 2021 Apr 10;40(1):125
SW620 cells 20, 40, 60 μM 48 h DEH significantly inhibited the proliferation and growth of SW620 cells by arresting the cell cycle at the G1/S phase. J Exp Clin Cancer Res. 2021 Apr 10;40(1):125
HCT 116 cells 20, 40, 60 μM 48 h DEH significantly inhibited the proliferation and growth of HCT 116 cells by arresting the cell cycle at the G1/S phase. J Exp Clin Cancer Res. 2021 Apr 10;40(1):125
NCM460 human normal intestinal epithelial cells 30 µM Evaluate the impact of DDIE on cell viability, results showed no cytotoxicity within the tested concentration range Acta Pharm Sin B. 2024 Dec;14(12):5286-5304

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Subcutaneous tumor-bearing mouse model Intraperitoneal injection 40 mg/kg Administered every other day for 2 weeks DHIE significantly reduced tumor burden, decreased Ki-67 infiltration level, and inhibited PLK1 expression Front Pharmacol. 2025 Feb 28;16:1545498
NOD/SCID mice CDX and PDX tumor xenograft models Intraperitoneal injection 40 mg/kg Once every other day for two weeks DEH significantly inhibited tumor growth in CDX and PDX models without affecting mouse body weight, indicating low toxicity. J Exp Clin Cancer Res. 2021 Apr 10;40(1):125
BALB/c mice CPT11-induced gut mucositis model Oral gavage 25 and 75 mg/kg Once daily for 12 days (Days 3–14) Evaluate the protective effect of DDIE against CPT11-induced gut mucositis, results showed DDIE significantly alleviated weight loss, colon shortening, epithelial barrier dysfunction, goblet cells and intestinal stem cells (ISCs) loss, and promoted wound healing Acta Pharm Sin B. 2024 Dec;14(12):5286-5304

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.06mL

0.61mL

0.31mL

15.32mL

3.06mL

1.53mL

30.64mL

6.13mL

3.06mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories